Allergan plc and Gedeon Richter Plc. announced they will present data on VRAYLAR (cariprazine) in patients with schizophrenia during the 54th American College of Neuropsychopharmacology (ACNP) Annual Meeting.
Data to be presented include additional analyses of cariprazine for the
potential treatment of predominant negative symptoms in patients with
schizophrenia. Also presented will be data investigating the metabolic
safety profile of cariprazine and its impact on long-term schizophrenia
relapse prevention.
VRAYLAR is an oral, once daily atypical antipsychotic approved for
the acute treatment of adult patients with manic or mixed episodes
associated with bipolar I disorder, with a recommended dose range of 3
to 6 mg/day and for the treatment of schizophrenia in adults, with a
recommended dose range of 1.5 to 6 mg/day. The safety and efficacy of
VRAYLAR was studied in a clinical trial program of more than 2,700
patients with these conditions.
Vraylar acts as a partial agonist at the dopamine D3 and D2 receptors. At antipsychotic doses, Vraylar shows high brain occupancy of both D3 and D2 receptors in schizophrenia patients. Vraylar is also a high affinity partial agonist at serotonin 5-HT1A receptors. In addition, Vraylar acts as an antagonist with high affinity at 5-HT2B receptors and moderate affinity at 5-HT2A and histamine H1 receptors . Vraylar shows lower binding affinity to the serotonin 5-HT2C and α1A- adrenergic receptors and has no appreciable affinity for cholinergic muscarinic receptors. VRAYLAR was discovered and co-developed by Gedeon Richter Plc and is licensed to Actavis, now Allergan, in the U.S. and Canada.
